Clinical Trial Update: Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 pilot study evaluating denileukin diftitox in combination with high-dose interleukin-2 for metastatic renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• ONTAK (denileukin diftitox)

Snippet

Sponsor: Northwestern University | Conditions: Kidney Cancer | EARLY_Phase 1 | Status: COMPLETED